Endpoints News· @endpts · X·· 11 天前精选AI 评分78
AI 导读
Sarepta表示不会恢复Elevidys确证性III期试验的入组。该试验自去年第二名患者死亡后一直处于暂停状态。
推荐理由
原文披露了Elevidys确证性III期试验暂停入组的状态,读者可据此了解该基因疗法临床推进受阻的现状。
正文
Sarepta won't resume enrollment in Elevidys' confirmatory Phase 3 trial, on hold since a second patient death last year. https://endpoints.news/sarepta-quits-enrolling-for-confirmatory-phase-3-trial-of-elevidys/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源:Endpoints News · x.com